CD274 and neoplasm: In CheckMate 032, the objective response rate (ORR) of the patients with tumor proportion score (TPS) of PD-L1 ≥1% was not significantly different from patients with TPS <1% (9.1% vs. 14.1% and 10% vs. 32.3%, respectively) in either Nivolumab group or Nivolumab + Ipilimumab group, revealing an irrelevance between PD-L1 expression and ORR (25).